Article Text

Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis. Comment on ‘Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis’ by Jonsson et al
  1. Maxime Chevreau1,
  2. Marie-Hélène Paclet2,3,
  3. Xavier Romand1,2,
  4. Jean-Louis Quesada4,5,
  5. Olivier Vittecoq6,
  6. Philippe Dieudé7,
  7. Bertrand Toussaint8,
  8. Philippe Gaudin1,2,
  9. Athan Baillet1,2
  1. 1Department of Rheumatology, Grenoble Alpes University Hospital, Grenoble, France
  2. 2Univ Grenoble Alpes, GREPI-UGA EA7408, Grenoble, France
  3. 3Lab. Biochimie des Enzymes et des Protéines, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
  4. 4INSERM, Clinical Investigation Center CIC P 1406, Grenoble Alpes University Hospital, Grenoble, France
  5. 5Scientific Department of the Clinical Research Delegation, Grenoble Alpes University Hospital, Grenoble, France
  6. 6Department of Rheumatology, Rouen Hospital, Bois-Guillaume, France
  7. 7Department of Rheumatology, Bichat Hospital, Paris, France
  8. 8Laboratoire TIMC-IMAG-TheREx, UMR 5525 Centre National de la Recherche Scientifique, Univ Grenoble Alpes, Grenoble, France
  1. Correspondence to Dr Athan Baillet, Rheumatology, Grenoble Alpes University Hospital, Université Grenoble Alpes, Echirolles 38434 Cedex, France; abaillet{at}

Statistics from

We have read with great interest the article by Jonsson et al that was recently published online in ARD,1 which suggested that calprotectin, also known as S100A8/S100A9 heterodimer, was associated with radiographic progression in early rheumatoid arthritis (RA). Calprotectin correlates significantly with inflammatory markers and disease activity score.2 Besides correlations between baseline calprotectin levels, Clinical Disease Activity Index and ultrasonography power Doppler, the authors showed that baseline calprotectin levels correlated with van der Heijde modified Sharp score (SHS) progression (defined as an increase ≥1 unit/year from 0 to 24 months), independently of age, gender, Clinical Disease Activity Index, erythrocyte sedimentation rate (ESR), C reactive protein (CRP) levels and rheumatoid factor positivity.1

We analysed the initial serum calprotectin among patients with early RA fulfilling American College of Rheumatology/European League Against Rheumatism 2010 of the French observational cohort Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR). Calprotectin serum concentrations were assessed according to manufacturer method (Hycult, Frontstraat, Netherlands; …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles